Serge Belanger joined Needham & Company in 2009, where he covers the Biotechnology sector. Prior to Needham, Serge worked as a research associate at Fulcrum Global Partners and Susquehanna International Group covering the biotech and specialty pharma healthcare sectors. Previously, Serge was part of Adolor Corporation, a biopharmaceutical company, as a senior research scientist, where he was involved with the discovery and development of novel opioid receptor targeted molecules and non-opioid pain therapeutics. Serge graduated from McGill University with a BSc, Biochemistry/Pharmacology, and an MSc, Pharmacology and Therapeutics. He obtained his MBA in Finance from the Stern School of Business at New York University.